MitoQ in sepsis-associated acute lung injury: redox pharmacology, mechanistic evidence, and translational perspectives
- 1Department of Pharmacology, Shaanxi University of Chinese Medicine , ,
Abstract
Sepsis-associated acute lung injury (SALI) is characterised by mitochondrial oxidative stress, bioenergetic dysfunction, dysregulated inflammation, and disruption of the alveolar–capillary barrier. MitoQ is a mitochondria-targeted redox modulator with experimental evidence of mitochondrial and pulmonary protection, making it a candidate strategy for limiting oxidative injury in SALI. This critical narrative review evaluates the redox pharmacology of MitoQ, direct pulmonary and sepsis-related evidence, mechanistic links between mitochondrial damage and innate immune signalling, and the major requirements for clinical translation. Available studies show that MitoQ reduces mitochondrial reactive oxygen species and lipid peroxidation, preserves membrane potential and ATP production, and attenuates epithelial, endothelial, and alveolar–capillary barrier injury. Mechanistic studies further support links among mitochondrial dysfunction, abnormal mitochondrial DNA exposure, cGAS–STING signalling, NLRP3–GSDMD activation, pyroptosis, and pulmonary barrier failure. However, these downstream pathways have not yet been causally linked to MitoQ treatment in infection-associated SALI, and pulmonary or intramitochondrial drug exposure remains poorly defined. Human studies demonstrate oral feasibility and systemic redox pharmacodynamic activity but have not established pulmonary target engagement or clinical efficacy. Current evidence therefore supports MitoQ primarily as an upstream mitochondrial redox modulator with potential to preserve alveolar–capillary function. Future studies should prioritise post-onset treatment, pulmonary and mitochondrial target engagement, pathway-specific causal validation, and assessment of host defence to determine its translational potential in SALI.
Related
- Natural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives
- Sulforaphane as a Therapeutic Target for Sarcopenia in Type 2 Diabetes: Mechanistic Insights and Translational Evidence.
- Microbiota–host crosstalk in ulcerative colitis: mechanistic evidence and translational prospects for traditional Chinese medicine
- Ubiquitin-specific proteases and the immune microenvironment in cervical cancer: mechanistic evidence, immunotherapy resistance, and therapeutic perspectives
- Evaluating traditional Chinese medicine modulation of the gut microbiota–bile acid axis in metabolic and inflammatory diseases: mechanistic evidence and translational priorities
BibTeX
@article{yu2026mitoq,
title = {{MitoQ in sepsis-associated acute lung injury: redox pharmacology, mechanistic evidence, and translational perspectives}},
author = {Jiajia Yu and Yuyu An and Yanni Mi and Guoquan Wang and Bin Wang and Jiping Liu},
journal = {Frontiers in pharmacology},
year = {2026},
month = sep,
doi = {10.3389/fphar.2026.1975929},
url = {https://europepmc.org/article/PMC/PMC13661397},
note = {CC BY},
}
RIS
TY - JOUR
TI - MitoQ in sepsis-associated acute lung injury: redox pharmacology, mechanistic evidence, and translational perspectives
AU - Jiajia Yu
AU - Yuyu An
AU - Yanni Mi
AU - Guoquan Wang
AU - Bin Wang
AU - Jiping Liu
PY - 2026
DA - 2026/09/30
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1975929
UR - https://europepmc.org/article/PMC/PMC13661397
AB - Sepsis-associated acute lung injury (SALI) is characterised by mitochondrial oxidative stress, bioenergetic dysfunction, dysregulated inflammation, and disruption of the alveolar–capillary barrier. MitoQ is a mitochondria-targeted redox modulator with experimental evidence of mitochondrial and pulmonary protection, making it a candidate strategy for limiting oxidative injury in SALI. This critical narrative review evaluates the redox pharmacology of MitoQ, direct pulmonary and sepsis-related evidence, mechanistic links between mitochondrial damage and innate immune signalling, and the major requirements for clinical translation. Available studies show that MitoQ reduces mitochondrial reactive oxygen species and lipid peroxidation, preserves membrane potential and ATP production, and attenuates epithelial, endothelial, and alveolar–capillary barrier injury. Mechanistic studies further support links among mitochondrial dysfunction, abnormal mitochondrial DNA exposure, cGAS–STING signalling, NLRP3–GSDMD activation, pyroptosis, and pulmonary barrier failure. However, these downstream pathways have not yet been causally linked to MitoQ treatment in infection-associated SALI, and pulmonary or intramitochondrial drug exposure remains poorly defined. Human studies demonstrate oral feasibility and systemic redox pharmacodynamic activity but have not established pulmonary target engagement or clinical efficacy. Current evidence therefore supports MitoQ primarily as an upstream mitochondrial redox modulator with potential to preserve alveolar–capillary function. Future studies should prioritise post-onset treatment, pulmonary and mitochondrial target engagement, pathway-specific causal validation, and assessment of host defence to determine its translational potential in SALI.
SN - 1663-9812
ER -